Now showing items 1-2 of 2

    • Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition 

      Weigert, Oliver; Bird, Liat; Kopp, Nadja; van Bodegom, Diederik; Marubayashi, Sachie; Christie, Amanda L.; Paranal, Ronald M.; Gaul, Christoph; Vangrevelinghe, Eric; Romanet, Vincent; Murakami, Masato; Tiedt, Ralph; Ebel, Nicolas; Evrot, Emeline; De Pover, Alain; Régnier, Catherine H.; Erdmann, Dirk; Hofmann, Francesco; Levine, Ross L.; Baffert, Fabienne; Radimerski, Thomas; Lane, Andrew Alan; Chapuy, Bjoern; Toms, Angela Vivian; McKeown, Michael Robert; Bradner, James Elliott; Yoda, Akinori; Eck, Michael Joseph; Sallan, Stephen Earl; Kung, Andrew; Weinstock, David Marc (The Rockefeller University Press, 2012)
      Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor ...
    • Next-Generation cDNA Screening for Oncogene and Resistance Phenotypes 

      Shindoh, Nobuaki; Weigert, Oliver; Bird, Liat; Yoda, Akinori; Yoda, Yuka; Sullivan, Timothy J.; Lane, Andrew Alan; Kopp, Nadja; Rodig, Scott J.; Fox, Edward Alvin; Weinstock, David Marc (Public Library of Science, 2012)
      There is a pressing need for methods to define the functional relevance of genetic alterations identified by next-generation sequencing of cancer specimens. We developed new approaches to efficiently construct full-length ...